| C028474 | 1,4-bis(2-(3,5-dichloropyridyloxy))benzene | "1,4-bis(2-(3,5-dichloropyridyloxy))benzene results in increased expression of MYLK mRNA" | 22698814 |
| C028474 | 1,4-bis(2-(3,5-dichloropyridyloxy))benzene | "NR1I3 protein promotes the reaction [1,4-bis(2-(3,5-dichloropyridyloxy))benzene results in increased expression of MYLK mRNA]" | 22698814 |
| C511295 | 2,2',4,4'-tetrabromodiphenyl ether | "2,2',4,4'-tetrabromodiphenyl ether analog results in increased expression of MYLK mRNA" | 19095052 |
| C093973 | 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one | 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one results in decreased activity of MYLK protein | 10733514 |
| C093973 | 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one | 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one results in decreased expression of MYLK protein | 18710790 |
| C511621 | 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide | 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [Particulate Matter results in decreased expression of MYLK mRNA] | 28655636 |
| C511621 | 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide | 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [Vehicle Emissions results in decreased expression of MYLK mRNA] | 28655636 |
| C017906 | 3-dinitrobenzene | 3-dinitrobenzene results in increased expression of MYLK mRNA | 24140754 |
| C459179 | 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide | "[NOG protein co-treated with entinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MYLK mRNA" | 27188386 |
| C459179 | 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide | "[NOG protein co-treated with mercuric bromide co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MYLK mRNA" | 27188386 |
| C459179 | 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide | "[NOG protein co-treated with panobinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MYLK mRNA" | 27188386 |
| C459179 | 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide | "[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MYLK mRNA" | 27188386 |
| C459179 | 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide | "[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MYLK mRNA" | 27188386 |
| C459179 | 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide | "[NOG protein co-treated with trichostatin A co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MYLK mRNA" | 27188386 |
| C459179 | 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide | "[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MYLK mRNA" | 27188386 |
| C027576 | 4-hydroxy-2-nonenal | 4-hydroxy-2-nonenal results in decreased expression of MYLK mRNA | 12419474 |
| C516138 | (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine | "[NOG protein co-treated with entinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MYLK mRNA" | 27188386 |
| C516138 | (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine | "[NOG protein co-treated with mercuric bromide co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MYLK mRNA" | 27188386 |
| C516138 | (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine | "[NOG protein co-treated with panobinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MYLK mRNA" | 27188386 |
| C516138 | (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine | "[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MYLK mRNA" | 27188386 |
| C516138 | (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine | "[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MYLK mRNA" | 27188386 |
| C516138 | (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine | "[NOG protein co-treated with trichostatin A co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MYLK mRNA" | 27188386 |
| C516138 | (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine | "[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MYLK mRNA" | 27188386 |
| D000082 | Acetaminophen | Acetaminophen results in decreased expression of MYLK mRNA | 21420995|2223033 |
| C109238 | acyline | acyline results in decreased expression of MYLK mRNA | 17510436 |
| D016604 | Aflatoxin B1 | Aflatoxin B1 affects the expression of MYLK protein | 20106945 |
| D016604 | Aflatoxin B1 | Aflatoxin B1 results in decreased expression of MYLK mRNA | 21632981|2164198 |
| D016604 | Aflatoxin B1 | Aflatoxin B1 results in increased methylation of MYLK gene | 27153756 |
| D018501 | Antirheumatic Agents | Antirheumatic Agents results in increased expression of MYLK mRNA | 24449571 |
| C006632 | arsenic trioxide | arsenic trioxide results in decreased expression of MYLK mRNA | 26238599 |
| D017638 | Asbestos, Crocidolite | "Asbestos, Crocidolite results in decreased expression of MYLK mRNA" | 25351596 |
| C547126 | AZM551248 | AZM551248 results in decreased expression of MYLK mRNA | 22323515 |
| C487081 | belinostat | belinostat results in decreased expression of MYLK mRNA | 26272509 |
| C022921 | benzo(k)fluoranthene | benzo(k)fluoranthene results in decreased expression of MYLK mRNA | 21635667 |
| D001564 | Benzo(a)pyrene | Benzo(a)pyrene results in decreased expression of MYLK mRNA | 20106945|2163298 |
| C072553 | benzyloxycarbonylleucyl-leucyl-leucine aldehyde | [MYBPC3 protein affects the susceptibility to benzyloxycarbonylleucyl-leucyl-leucine aldehyde] which results in decreased expression of MYLK mRNA | 25566086 |
| D004958 | Estradiol | [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of MYLK mRNA | 20823114 |
| D004958 | Estradiol | [Estradiol co-treated with Progesterone] results in decreased expression of MYLK mRNA | 20660070 |
| D004958 | Estradiol | [Progesterone co-treated with Estradiol] results in decreased expression of MYLK mRNA | 17404688 |
| D004958 | Estradiol | [Estradiol co-treated with Progesterone] results in decreased expression of MYLK mRNA | 19687787 |
| D004958 | Estradiol | Estradiol results in decreased expression of MYLK mRNA | 19687787 |
| D004958 | Estradiol | Estradiol inhibits the reaction [Lipopolysaccharides results in increased expression of MYLK mRNA] | 16977382 |
| C006780 | bisphenol A | bisphenol A affects the expression of MYLK mRNA | 25181051 |
| D020122 | tert-Butylhydroperoxide | tert-Butylhydroperoxide affects the expression of MYLK mRNA | 23410634 |
| D020122 | tert-Butylhydroperoxide | tert-Butylhydroperoxide results in decreased expression of MYLK mRNA | 12419474 |
| C018475 | butyraldehyde | butyraldehyde results in decreased expression of MYLK mRNA | 26079696 |
| D019256 | Cadmium Chloride | Cadmium Chloride results in increased expression of MYLK mRNA | 23741332 |
| D002118 | Calcium | Calcium deficiency results in increased activity of MYLK protein | 11054866 |
| D002118 | Calcium | Calcium results in increased activity of MYLK protein | 10640419 |
| D002118 | Calcium | ML 7 inhibits the reaction [Calcium deficiency results in increased activity of MYLK protein] | 11054866 |
| D002118 | Calcium | [[Calcium results in increased activity of MYLK protein] which results in increased phosphorylation of MYL9 protein] which results in decreased secretion of REN protein | 9618396 |
| D002118 | Calcium | [ML 7 results in decreased activity of MYLK protein] which results in decreased uptake of Calcium | 9506478 |
| D002118 | Calcium | [ML 9 results in decreased activity of MYLK protein] which results in decreased uptake of Calcium | 9506478 |
| D002118 | Calcium | MYLK protein affects the uptake of Calcium | 9506478 |
| D002217 | Carbachol | Carbachol results in increased phosphorylation of MYLK protein | 15939040 |
| D002217 | Carbachol | ML 7 inhibits the reaction [Carbachol results in increased phosphorylation of MYLK protein] | 15939040 |
| D002217 | Carbachol | MYLK protein affects the susceptibility to Carbachol | 17272850 |
| D002220 | Carbamazepine | Carbamazepine affects the expression of MYLK mRNA | 25979313 |
| D020245 | p-Chloromercuribenzoic Acid | "[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MYLK mRNA" | 27188386 |
| D020245 | p-Chloromercuribenzoic Acid | p-Chloromercuribenzoic Acid results in decreased expression of MYLK mRNA | 26272509 |
| D002772 | Cholera Toxin | Cholera Toxin results in decreased activity of MYLK protein | 9572834 |
| D002784 | Cholesterol | Cholesterol results in increased activity of MYLK protein | 21052790 |
| D002784 | Cholesterol | Cholesterol results in increased expression of MYLK protein | 21052790 |
| D002784 | Cholesterol | ML 7 inhibits the reaction [Cholesterol results in increased activity of MYLK protein] | 21052790 |
| C031180 | chrysene | chrysene results in increased expression of MYLK mRNA | 26377693 |
| C018021 | cobaltous chloride | cobaltous chloride results in decreased expression of MYLK mRNA | 24386269 |
| C018021 | cobaltous chloride | cobaltous chloride results in decreased expression of MYLK protein | 24386269 |
| D003300 | Copper | [Disulfiram binds to Copper] which results in increased expression of MYLK mRNA | 24690739 |
| D003300 | Copper | [NSC 689534 binds to Copper] which results in increased expression of MYLK mRNA | 20971185 |
| D003471 | Cuprizone | Cuprizone affects the expression of MYLK mRNA | 26577399 |
| D003474 | Curcumin | Curcumin results in increased expression of MYLK mRNA | 21594647 |
| D003513 | Cycloheximide | Cycloheximide inhibits the reaction [TNF protein results in increased expression of MYLK protein] | 15701621 |
| D016572 | Cyclosporine | Cyclosporine affects the expression of MYLK mRNA | 25562108 |
| D016572 | Cyclosporine | Cyclosporine results in decreased expression of MYLK mRNA | 20106945|2798913 |
| D016572 | Cyclosporine | Cyclosporine results in decreased expression of MYLK mRNA | 19770486 |
| D003609 | Dactinomycin | Dactinomycin inhibits the reaction [TNF protein results in increased expression of MYLK mRNA] | 15701621 |
| D003609 | Dactinomycin | Dactinomycin inhibits the reaction [TNF protein results in increased expression of MYLK protein] | 15701621 |
| D000069439 | Dasatinib | Dasatinib results in increased expression of MYLK mRNA | 20579391 |
| C014347 | decitabine | decitabine affects the expression of MYLK mRNA | 17145863 |
| D003907 | Dexamethasone | Dexamethasone results in increased expression of MYLK mRNA | 25047013 |
| D003994 | Bucladesine | [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of MYLK mRNA | 20823114 |
| D002945 | Cisplatin | [Cisplatin co-treated with jinfukang] results in increased expression of MYLK mRNA | 27392435 |
| D002945 | Cisplatin | Cisplatin results in increased expression of MYLK mRNA | 27392435 |
| D004026 | Dieldrin | Dieldrin results in increased expression of MYLK mRNA | 20438755 |
| D004041 | Dietary Fats | Dietary Fats results in increased expression of MYLK mRNA | 18042831 |
| D004041 | Dietary Fats | [Dietary Fats co-treated with resveratrol] results in increased expression of MYLK mRNA | 21852083 |
| D004051 | Diethylhexyl Phthalate | Diethylhexyl Phthalate results in decreased expression of MYLK mRNA | 19850644 |
| D004051 | Diethylhexyl Phthalate | PPARA protein promotes the reaction [Diethylhexyl Phthalate results in decreased expression of MYLK mRNA] | 19850644 |
| D004077 | Digoxin | [ML 7 results in decreased activity of MYLK protein] affects the reaction [ABCB1 protein affects the transport of Digoxin] | 20510202 |
| D002117 | Calcitriol | Calcitriol results in increased expression of MYLK mRNA | 21592394 |
| D002117 | Calcitriol | [Testosterone co-treated with Calcitriol] results in increased expression of MYLK mRNA | 21592394 |
| C472511 | dimethylarsinous acid | dimethylarsinous acid results in decreased expression of MYLK mRNA | 16507463 |
| D019813 | 1,2-Dimethylhydrazine | "[APC protein affects the susceptibility to 1,2-Dimethylhydrazine] which results in increased expression of MYLK mRNA" | 27840820 |
| D004221 | Disulfiram | [Disulfiram binds to Copper] which results in increased expression of MYLK mRNA | 24690739 |
| D004237 | Diuron | Diuron results in decreased expression of MYLK mRNA | 25152437 |
| D004237 | Diuron | Diuron results in increased expression of MYLK mRNA | 21551480 |
| D004317 | Doxorubicin | Doxorubicin results in decreased expression of MYLK protein | 12717111 |
| D004642 | Emodin | Emodin results in increased activity of MYLK protein | 15133857 |
| C118739 | entinostat | entinostat results in decreased expression of MYLK mRNA | 26272509 |
| C118739 | entinostat | "[NOG protein co-treated with entinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MYLK mRNA" | 27188386 |
| D000431 | Ethanol | Ethanol results in increased activity of MYLK protein | 10198341 |
| D000431 | Ethanol | Ethanol results in increased expression of MYLK mRNA | 25226407 |
| D000431 | Ethanol | ML 7 inhibits the reaction [Ethanol results in increased activity of MYLK protein] | 10198341 |
| D004997 | Ethinyl Estradiol | Ethinyl Estradiol results in decreased expression of MYLK mRNA | 17557909 |
| D011345 | Fenofibrate | Fenofibrate results in decreased expression of MYLK mRNA | 25572481 |
| C039281 | furan | furan results in decreased expression of MYLK mRNA | 25539665 |
| D019833 | Genistein | Genistein results in decreased expression of MYLK mRNA | 22228119 |
| C049864 | ginsenoside Re | ginsenoside Re affects the expression of MYLK mRNA | 24658813 |
| C049864 | ginsenoside Re | ginsenoside Re affects the expression of MYLK protein | 24658813 |
| D005897 | Glafenine | Glafenine results in decreased expression of MYLK mRNA | 24136188 |
| D005947 | Glucose | ML 7 inhibits the reaction [MYLK protein results in increased uptake of Glucose] | 18773891 |
| D005947 | Glucose | ML 9 inhibits the reaction [MYLK protein results in increased uptake of Glucose] | 18773891 |
| D005947 | Glucose | MYLK protein results in increased uptake of Glucose | 18773891 |
| D017313 | Fenretinide | Fenretinide results in increased expression of MYLK mRNA | 28973697 |
| D012701 | Serotonin | MYLK protein affects the susceptibility to Serotonin | 14690016 |
| D006861 | Hydrogen Peroxide | Hydrogen Peroxide affects the expression of MYLK mRNA | 23410634 |
| C041508 | indeno(1,2,3-cd)pyrene | "indeno(1,2,3-cd)pyrene results in decreased expression of MYLK mRNA" | 21635667 |
| C544151 | jinfukang | [Cisplatin co-treated with jinfukang] results in increased expression of MYLK mRNA | 27392435 |
| C544151 | jinfukang | jinfukang results in increased expression of MYLK mRNA | 27392435 |
| C098607 | JP8 aviation fuel | JP8 aviation fuel affects the expression of MYLK mRNA | 15476862 |
| C561695 | (+)-JQ1 compound | (+)-JQ1 compound results in decreased expression of MYLK mRNA | 24796395 |
| C063769 | KT 5926 | KT 5926 results in decreased activity of MYLK protein | 9572834 |
| C063769 | KT 5926 | [KT 5926 results in decreased activity of MYLK protein] inhibits the reaction [TNF protein results in increased expression of SELE mRNA] | 15526279 |
| D008070 | Lipopolysaccharides | Estradiol inhibits the reaction [Lipopolysaccharides results in increased expression of MYLK mRNA] | 16977382 |
| D008070 | Lipopolysaccharides | Lipopolysaccharides results in increased expression of MYLK mRNA | 16977382|1937478 |
| D008070 | Lipopolysaccharides | Lipopolysaccharides results in increased expression of MYLK protein | 19374788 |
| D008070 | Lipopolysaccharides | ML 7 inhibits the reaction [Lipopolysaccharides results in increased expression of MYLK mRNA] | 19374788 |
| D008070 | Lipopolysaccharides | ML 7 inhibits the reaction [Lipopolysaccharides results in increased expression of MYLK protein] | 19374788 |
| D008070 | Lipopolysaccharides | MYLK protein affects the susceptibility to Lipopolysaccharides | 16192642 |
| D019808 | Losartan | Losartan inhibits the reaction [AGT protein results in increased expression of MYLK protein] | 18511912 |
| C032881 | lysophosphatidic acid | MYLK protein affects the susceptibility to lysophosphatidic acid | 10640419 |
| C032881 | lysophosphatidic acid | MYLK protein affects the susceptibility to lysophosphatidic acid | 11274070 |
| C018091 | maduramicin | maduramicin results in decreased expression of MYLK mRNA | 29128925 |
| D058185 | Magnetite Nanoparticles | [Succimer co-treated with Magnetite Nanoparticles] results in increased expression of MYLK mRNA | 26378955 |
| D017258 | Medroxyprogesterone Acetate | [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of MYLK mRNA | 20823114 |
| C042720 | mercuric bromide | mercuric bromide results in decreased expression of MYLK mRNA | 26272509 |
| C042720 | mercuric bromide | "[NOG protein co-treated with mercuric bromide co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MYLK mRNA" | 27188386 |
| D008694 | Methamphetamine | Methamphetamine results in increased expression of MYLK mRNA | 26307267 |
| D008694 | Methamphetamine | Methamphetamine affects the expression of MYLK mRNA | 19564919 |
| D008694 | Methamphetamine | [Methamphetamine co-treated with SCH 23390] affects the expression of MYLK mRNA | 19564919 |
| C013598 | methoxyacetic acid | methoxyacetic acid results in increased expression of MYLK protein | 11794376 |
| C005219 | methyl cellosolve | methyl cellosolve metabolite results in increased expression of MYLK protein | 11794376 |
| D008748 | Methylcholanthrene | [Methylcholanthrene co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of MYLK mRNA | 23519560 |
| C004925 | methylmercuric chloride | methylmercuric chloride results in increased expression of MYLK mRNA | 23103053 |
| C004925 | methylmercuric chloride | methylmercuric chloride results in decreased expression of MYLK mRNA | 28001369 |
| D008769 | Methylnitronitrosoguanidine | Methylnitronitrosoguanidine results in decreased expression of MYLK mRNA | 12634122 |
| C070571 | ML 7 | ML 7 inhibits the reaction [Carbachol results in increased phosphorylation of MYLK protein] | 15939040 |
| C070571 | ML 7 | ML 7 results in decreased activity of MYLK protein | 9572834 |
| C070571 | ML 7 | [ML 7 results in decreased activity of MYLK protein] inhibits the reaction [TNF protein affects the localization of RELA protein] | 15526279 |
| C070571 | ML 7 | [ML 7 results in decreased activity of MYLK protein] inhibits the reaction [TNF protein results in increased activity of RELA protein] | 15526279 |
| C070571 | ML 7 | [ML 7 results in decreased activity of MYLK protein] inhibits the reaction [TNF protein results in increased degradation of NFKBIA protein] | 15526279 |
| C070571 | ML 7 | [ML 7 results in decreased activity of MYLK protein] inhibits the reaction [TNF protein results in increased expression of SELE mRNA] | 15526279 |
| C070571 | ML 7 | [ML 7 results in decreased activity of MYLK protein] affects the reaction [ABCB1 protein affects the transport of Digoxin] | 20510202 |
| C070571 | ML 7 | ML 7 results in decreased activity of MYLK protein | 17509155 |
| C070571 | ML 7 | FADD protein affects the reaction [[ML 7 results in decreased activity of MYLK protein] which results in increased activity of CASP3 protein] | 16723733 |
| C070571 | ML 7 | ML 7 inhibits the reaction [Calcium deficiency results in increased activity of MYLK protein] | 11054866 |
| C070571 | ML 7 | ML 7 inhibits the reaction [Ethanol results in increased activity of MYLK protein] | 10198341 |
| C070571 | ML 7 | ML 7 results in decreased activity of MYLK protein | 10733514|1253434 |
| C070571 | ML 7 | [ML 7 results in decreased activity of MYLK protein] which results in decreased activity of F2 protein | 16675616 |
| C070571 | ML 7 | [ML 7 results in decreased activity of MYLK protein] which results in decreased phosphorylation of MYL9 protein | 1643115 |
| C070571 | ML 7 | [ML 7 results in decreased activity of MYLK protein] which results in increased activity of CASP3 protein | 16723733 |
| C070571 | ML 7 | ML 7 inhibits the reaction [Lipopolysaccharides results in increased expression of MYLK mRNA] | 19374788 |
| C070571 | ML 7 | ML 7 inhibits the reaction [Lipopolysaccharides results in increased expression of MYLK protein] | 19374788 |
| C070571 | ML 7 | ML 7 inhibits the reaction [MYLK protein results in increased uptake of Glucose] | 18773891 |
| C070571 | ML 7 | ML 7 results in decreased activity of MYLK protein | 19943851 |
| C070571 | ML 7 | ML 7 inhibits the reaction [Cholesterol results in increased activity of MYLK protein] | 21052790 |
| C070571 | ML 7 | ML 7 results in decreased activity of MYLK protein | 17541957 |
| C070571 | ML 7 | [ML 7 results in decreased activity of MYLK protein] which results in decreased phosphorylation of MYL9 protein | 18835913 |
| C070571 | ML 7 | [[ML 7 results in decreased activity of MYLK protein] which results in decreased phosphorylation of MYL9 protein] which results in increased secretion of REN protein | 9618396 |
| C070571 | ML 7 | [ML 7 results in decreased activity of MYLK protein] which results in decreased uptake of Calcium | 9506478 |
| C056218 | ML 9 | FADD protein affects the reaction [[ML 9 results in decreased activity of MYLK protein] which results in increased activity of CASP3 protein] | 16723733 |
| C056218 | ML 9 | ML 9 results in decreased activity of MYLK protein | 12534346 |
| C056218 | ML 9 | [ML 9 results in decreased activity of MYLK protein] which results in increased activity of CASP3 protein | 16723733 |
| C056218 | ML 9 | ML 9 inhibits the reaction [MYLK protein results in increased uptake of Glucose] | 18773891 |
| C056218 | ML 9 | [ML 9 results in decreased activity of MYLK protein] which results in decreased uptake of Calcium | 9506478 |
| C406082 | monomethylarsonous acid | monomethylarsonous acid results in decreased expression of MYLK mRNA | 16507463|2088654 |
| D037742 | Nanotubes, Carbon | "Nanotubes, Carbon analog results in decreased expression of MYLK mRNA" | 25620056 |
| D037742 | Nanotubes, Carbon | "Nanotubes, Carbon results in decreased expression of MYLK mRNA" | 25620056 |
| D009532 | Nickel | Nickel results in decreased expression of MYLK mRNA | 24768652|2558310 |
| D009532 | Nickel | Nickel results in increased expression of MYLK mRNA | 18922574 |
| C572573 | N-nitroso-tris-chloroethylurea | [N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of MYLK mRNA | 27935865 |
| C558013 | NSC 689534 | [NSC 689534 binds to Copper] which results in increased expression of MYLK mRNA | 20971185 |
| C030110 | oxaliplatin | [oxaliplatin co-treated with Topotecan] results in increased expression of MYLK mRNA | 25729387 |
| D010100 | Oxygen | Oxygen deficiency results in decreased phosphorylation of MYLK protein | 18375742 |
| D000073878 | Palm Oil | Palm Oil results in increased expression of MYLK mRNA | 18042831 |
| C496932 | panobinostat | "[NOG protein co-treated with panobinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MYLK mRNA" | 27188386 |
| C496932 | panobinostat | panobinostat results in decreased expression of MYLK mRNA | 26272509 |
| D052638 | Particulate Matter | 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [Particulate Matter results in decreased expression of MYLK mRNA] | 28655636 |
| D052638 | Particulate Matter | Particulate Matter results in decreased expression of MYLK mRNA | 28341207|2865563 |
| C027579 | periodate-oxidized adenosine | periodate-oxidized adenosine affects the expression of MYLK mRNA | 17097637 |
| C076715 | pervanadate | MYLK protein affects the susceptibility to pervanadate | 12020688 |
| D010578 | Petroleum | Petroleum affects the expression of MYLK mRNA | 25208076 |
| D010662 | Phenylmercuric Acetate | "[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MYLK mRNA" | 27188386 |
| D010662 | Phenylmercuric Acetate | Phenylmercuric Acetate results in decreased expression of MYLK mRNA | 26272509 |
| C060836 | pioglitazone | [N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of MYLK mRNA | 27935865 |
| C006253 | pirinixic acid | [pirinixic acid binds to and results in increased activity of PPARA protein] which results in increased expression of MYLK mRNA | 19710929 |
| C006253 | pirinixic acid | pirinixic acid results in decreased expression of MYLK mRNA | 23811191 |
| D011374 | Progesterone | Progesterone results in decreased expression of MYLK mRNA | 23012394|2301818 |
| D011374 | Progesterone | [Estradiol co-treated with Progesterone] results in decreased expression of MYLK mRNA | 20660070 |
| D011374 | Progesterone | [Progesterone co-treated with Estradiol] results in decreased expression of MYLK mRNA | 17404688 |
| D011374 | Progesterone | [Estradiol co-treated with Progesterone] results in decreased expression of MYLK mRNA | 19687787 |
| C045950 | propiconazole | propiconazole results in decreased expression of MYLK mRNA | 21278054 |
| D011441 | Propylthiouracil | Propylthiouracil affects the expression of MYLK mRNA | 24780913 |
| D011794 | Quercetin | Quercetin results in decreased expression of MYLK mRNA | 21632981 |
| C059514 | resveratrol | [Dietary Fats co-treated with resveratrol] results in increased expression of MYLK mRNA | 21852083 |
| C534628 | SCH 23390 | [Methamphetamine co-treated with SCH 23390] affects the expression of MYLK mRNA | 19564919 |
| C534628 | SCH 23390 | SCH 23390 results in decreased expression of MYLK mRNA | 19564919 |
| D012715 | Sesame Oil | Sesame Oil results in decreased expression of MYLK mRNA | 29191790 |
| D012822 | Silicon Dioxide | Silicon Dioxide results in decreased expression of MYLK mRNA | 25351596 |
| D020123 | Sirolimus | Sirolimus inhibits the reaction [TP73 protein results in increased expression of MYLK mRNA] | 21245298 |
| C009277 | sodium arsenate | sodium arsenate results in increased expression of MYLK mRNA | 21795629 |
| C017947 | sodium arsenite | sodium arsenite results in decreased expression of MYLK mRNA | 16507463 |
| C016104 | sodium bichromate | sodium bichromate affects the expression of MYLK mRNA | 22110744 |
| D012969 | Sodium Fluoride | Sodium Fluoride results in decreased expression of MYLK protein | 28918527 |
| D010042 | Ouabain | Ouabain results in decreased expression of MYLK mRNA | 28795476 |
| D004113 | Succimer | [Succimer co-treated with Magnetite Nanoparticles] results in increased expression of MYLK mRNA | 26378955 |
| D013739 | Testosterone | [Testosterone co-treated with Calcitriol] results in increased expression of MYLK mRNA | 21592394 |
| D013739 | Testosterone | Testosterone results in increased expression of MYLK mRNA | 21592394 |
| D013749 | Tetrachlorodibenzodioxin | Tetrachlorodibenzodioxin affects the expression of MYLK mRNA | 21570461 |
| D013749 | Tetrachlorodibenzodioxin | Tetrachlorodibenzodioxin affects the expression of MYLK mRNA | 22298810 |
| D013755 | Tetradecanoylphorbol Acetate | [Methylcholanthrene co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of MYLK mRNA | 23519560 |
| D013792 | Thalidomide | Thalidomide results in increased expression of MYLK mRNA | 26217789 |
| D013853 | Thioacetamide | Thioacetamide results in decreased expression of MYLK mRNA | 23411599 |
| C009495 | titanium dioxide | titanium dioxide results in increased expression of MYLK mRNA | 23557971 |
| D019772 | Topotecan | [oxaliplatin co-treated with Topotecan] results in increased expression of MYLK mRNA | 25729387 |
| D019772 | Topotecan | Topotecan results in increased expression of MYLK mRNA | 25729387 |
| D014212 | Tretinoin | Tretinoin results in decreased expression of MYLK mRNA | 21934132 |
| C012589 | trichostatin A | "[NOG protein co-treated with trichostatin A co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MYLK mRNA" | 27188386 |
| C012589 | trichostatin A | trichostatin A results in decreased expression of MYLK mRNA | 24935251|2627250 |
| C012589 | trichostatin A | trichostatin A results in increased expression of MYLK mRNA | 24935251|2623859 |
| C016805 | tris(1,3-dichloro-2-propyl)phosphate | "tris(1,3-dichloro-2-propyl)phosphate results in decreased expression of MYLK mRNA" | 26179874 |
| C113580 | U 0126 | U 0126 inhibits the reaction [AGT protein results in increased expression of MYLK protein] | 18511912 |
| D014520 | Urethane | Urethane results in decreased expression of MYLK mRNA | 28818685 |
| D014635 | Valproic Acid | "[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MYLK mRNA" | 27188386 |
| D014635 | Valproic Acid | Valproic Acid affects the expression of MYLK mRNA | 25979313 |
| D014635 | Valproic Acid | Valproic Acid results in decreased expression of MYLK mRNA | 23179753|2438349 |
| D014635 | Valproic Acid | Valproic Acid results in increased expression of MYLK mRNA | 23179753|2493525 |
| D014667 | Vasopressins | MYLK protein affects the susceptibility to Vasopressins | 15347643 |
| D001335 | Vehicle Emissions | 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [Vehicle Emissions results in decreased expression of MYLK mRNA] | 28655636 |
| D001335 | Vehicle Emissions | Vehicle Emissions results in decreased expression of MYLK mRNA | 28655636 |
| D001335 | Vehicle Emissions | Vehicle Emissions results in decreased methylation of MYLK gene | 25487561 |
| C025643 | vinclozolin | vinclozolin affects the expression of MYLK mRNA | 19015723 |
| D014800 | Vitallium | Vitallium analog results in increased expression of MYLK mRNA | 23825117 |
| D024483 | Vitamin K 3 | Vitamin K 3 affects the expression of MYLK mRNA | 23410634 |
| C111237 | vorinostat | vorinostat results in increased expression of MYLK mRNA | 26238599 |
| D014874 | Water Pollutants, Chemical | "Water Pollutants, Chemical affects the expression of MYLK mRNA" | 25208076 |